NCT06196918View on ClinicalTrials.gov

Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients

NARecruitingINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

August 31, 2024

Study Completion Date

February 28, 2025

Conditions
Glioma, Malignant
Interventions
DRUG

Rivaroxaban 10 MG

Patients with postoperative lower extremity dyskinesia are treated with rivaroxaban (10 mg/day) and compression stockings until 1 month after surgery.

DRUG

Placebo

Patients with postoperative lower extremity dyskinesia are treated with placebo (10 mg/day) and compression stockings until 1 month after surgery.

Trial Locations (8)

100070

RECRUITING

Beijing Tiantan Hospital, Beijing

210029

RECRUITING

The First Affiliated Hospital of Nanjing Medical University, Nanjing

350001

RECRUITING

Fujian provincial hospital, Fuzhou

515041

RECRUITING

The First Affiliated Hospital of Shantou University Medical College, Shantou

518116

RECRUITING

Longgang Central Hospital of Shenzhen, Shenzhen

528000

RECRUITING

The First People's Hospital of Foshan, Foshan

530021

RECRUITING

Guangxi Medical University Cancer Hospital, Nanning

570311

RECRUITING

Hainan general hospital, Haikou

All Listed Sponsors
lead

Nanfang Hospital, Southern Medical University

OTHER